This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
CVBT-141H (Catheter Delivery)
CardioVascular BioTherapeutics Inc.
Drug Names(s): CVBT-141A (Surgical Delivery), Fibroblast Growth Factor-1 (FGF-1), FGF 1-141
Description: CVBT-141H was bridged from CVBT-141A which used an injection delivery method. CVBT-141A, a protein, is a member of the fibroblast growth factor family. Fibroblast Growth Factor-1 or FGF-1, is a powerful stimulator of angiogenesis. FGF-1 stimulates the growth and multiplication of the two main cell types of blood vessels, smooth muscle cells and endothelial cells.
Deal Structure: In November 2008, CardioVascular BioTherapeutics entered into its first clinical development agreement for its Coronary Heart Disease drug candidate with Cardio Neo-Genesis, LP (CNG). The agreement states that CNG can fund up to $15,000,000 of the clinical development for the Company's Coronary Heart Disease (CHD) drug candidate. The agreement also provides for a royalty to CNG payable from 5% of CVBT's cash-flow stream on its CHD drug up to 20 times return to CNG's limited partners.
CVBT-141H (Catheter Delivery) News
Additional information available to subscribers only: